Corrigendum to "Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: An open treatment trial" [Epilepsy Behav 2006;8:659-62] (DOI:10.1016/j.yebeh.2006.01.015);Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: An open treatment trial

Epilepsy and Behavior

Volumn 8, Issue 3, 2006, Pages 659-662

  van der Feltz Cornelis, C M ^a   Aldenkamp, A P ^b,c  

^a STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

Adult attention deficit hyperactivity disorder; Comorbidity; Effectiveness; Epilepsy; Methylphenidate; Open treatment study; Psychogenic non epileptic seizures; Safety; Seizure frequency

Indexed keywords

ANTICONVULSIVE AGENT; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PSYCHOGENESIS; SEIZURE; SYMPTOMATOLOGY; TACHYCARDIA;

EID: 33646085103     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2006.01.021     Document Type: Erratum

References (20)

1. Pellock J.M. Understanding co-morbidities affecting children with epilepsy. Neurology 62 5 Suppl. 2 (2004) S17-S23
2. Kooij J.J., Buitelaar J.K., Van den Oord E.J., Furer J.W., Rijnders C.A., and Hodiamont P.P. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 35 6 (2005) 817-827
3. Kooij J.J., Aeckerlin L.P., and Buitelaar J.K. Functioning, co-morbidity and treatment of 141 adults with attention deficit disorder (ADHD) at a psychiatric outpatient department. Ned Tijdschr Geneesk 145 31 (2001) 1498-1501
4. Kooij J.J., Goekoop J.G., and Gunning W.B. Attention deficit disorders with hyperactivity in adulthood; implications for diagnosis and treatment. Ned Tijdschr Geneeskd 140 37 (1996) 1848-1851
5. Stein M.A., Blondis T.A., Schnitzler E.R., et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98 (1996) 748-756
6. Tavakoli S.A., and Gleason O.C. Seizures associated with venlafaxine, methylphenidate, and zolpidem. Psychosomatics 44 3 (2003) 262-264
7. Gucuyener K., Kemal Erdemogu A., Senol S., Serdaroglu A., Soysal S., and Kockar I. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 18 (2003) 109-112
8. Feldman H., Crumrine P., Handen B.L., et al. Methylphenidate in children with seizures and attention deficit disorder. Am J Dis Child 143 (1989) 1081-1086
9. Mc Bride M., and West Torres C. Methylphenidate in therapeutic doses does not lower threshold. Ann Neurol 20 (1986) 428
10. Van der Feltz-Cornelis C.M. Intractable obsessive-compulsive disorder: co-morbidity with unrecognized adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 187 4 (1999) 243-245
11. Moore J.L., McAuley J.W., Long L., and Bornstein R. An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav 3 1 (2002) 92-95
12. Robins L.N., Wing J., Wittchen H.U., et al. The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45 12 (1988) 1069-1077
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC, APA, 1994.
14. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
15. Hesdorffer D.C., Ludvigsson P., Olafsson E., et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 61 7 (2004) 731-736
16. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 3 10 (2004) 618-621
17. Kwan P., and Brodie M.J. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45 9 (2004) 1141-1149
18. Asconape J.J. Some common issues in the use of antiepileptic drugs. Semin Neurol 22 1 (2002) 27-39 [Review]
19. Brunbech L., and Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 62 4 (2002) 593-604 [Review]
20. Aldenkamp A.P., De Krom M., and Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 44 Suppl.4 (2003) 21-29